116748-66-4

Basic information

• Product Name: 4'-FLUORO[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE
• Synonyms: BUTTPARK 99\57-74;[4-(4-FLUOROPHENYL)PHENYL]SULFONYL CHLORIDE;4'-FLUORO[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE;4'-FLUORO-BIPHENYL-4-SULFONYL CHLORIDE;[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE, 4'-FLUORO-;4-(Fluorophenyl)benzenesulphonyl chloride;4-(4-fluorophenyl)benzenesulfonyl chloride;4'-Fluorobiphenyl-4-sulfonyl chloride 95%
• CAS NO: 116748-66-4
• Molecular Formula: C₁₂H₈ClFO₂S
• Molecular Weight: 270.71
• Product Categories: Aryl Fluorinated Building Blocks;Building Blocks;C8-C12;Chemical Synthesis;Fluorinated Building Blocks;Organic Fluorinated Building Blocks;Other Fluorinated Organic Building Blocks
• Mol File: 116748-66-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 82 °C
• Boiling Point: 372.859 °C at 760 mmHg
• Flash Point: 179.299 °C
• Appearance: /
• Density: 1.384 g/cm³
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 4'-FLUORO[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-FLUORO[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE(116748-66-4)
• EPA Substance Registry System: 4'-FLUORO[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE(116748-66-4)

Safety Data

• Hazard Codes: C
• Statements: 14-34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8 / PGII
• WGK Germany: 3
• HazardClass: 8
• Hazardous Substances Data: 116748-66-4(Hazardous Substances Data)

Usage

General Description

4'-Fluoro[1,1'-biphenyl]-4-sulfonyl chloride is a chemical compound with the molecular formula C12H8ClFO2S. It is a sulfonyl chloride derivative of biphenyl, which is commonly used in the production of pharmaceuticals and agrochemicals as a building block in organic synthesis. 4'-FLUORO[1,1'-BIPHENYL]-4-SULFONYL CHLORIDE is used as a versatile intermediate in the synthesis of various biologically active molecules, including pharmaceuticals, dyes, and advanced materials. It is a highly reactive compound that can be used in the production of a wide range of chemical products. Due to its properties, it is important to handle this compound with caution, as it can be corrosive and harmful if not used properly.

Upstream product

• 324-74-3 4-fluoro-biphenyl 
• 777056-02-7 4'-fluorobiphenyl-4-sulfonic acid 

Downstream Products

• 1158989-68-4 1,1-dimethylethyl (2S)-4-[(4-{[(4'-fluoro-4-biphenylyl)sulfonyl]amino}phenyl)methyl]-2-methyl-1-piperazinecarboxylate 
• 1158989-67-3 1,1-dimethylethyl (2S)-4-({4-[[(4'-fIuoro-4-biphenylyl)sulfonyl](methyl)amino]phenyl}methyl)-2-methyl-1-piperazinecarboxylate 
• 1456602-11-1 5-(2-(4'-fluoro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-heptylbenzyl)acetamido)-2-hydroxybenzoic acid 
• 1456601-89-0 methyl 5-(2-(4'-fluoro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-heptylbenzyl)acetamido)-2-hydroxybenzoate 
• 220441-09-8 1-(4'-fluorobiphenyl-4-sulfonylamino) cyclopentanecarboxylic acid benzyl ester 
• 116748-25-5 C₆₄H₅₈F₂N₄O₆S₂ 
• 253194-89-7 (S)-4-(4'-Fluoro-biphenyl-4-sulfonyl)-2,2-dimethyl-[1,4]thiazepane-3-carboxylic acid 
• 116748-58-4 4'-Fluoro-biphenyl-4-sulfonic acid 2-formyl-phenyl ester 

Relevant articles and documents

Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13

The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis. Our efforts have resulted in the discovery of a series of carboxylic acid inhibitors of MMP-13 that do not significantly inhibit the related MMP-1 (collagenase-1) or tumor necrosis factor-α (TNF-α) converting enzyme (TACE). It has previously been suggested (but not proven) that inhibition of the latter two enzymes could lead to side effects. A promising carboxylic acid lead 9 was identified and a convergent synthesis developed. This paper describes the optimization of 9 and the identification of a compound 24f for further development. Compound 24f is a subnanomolar inhibitor of MMP-13 (IC50 value 0.5 nM and Ki of 0.19 nM) having no activity against MMP-1 or TACE (IC50 of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 24f significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p 0.05) and at 10 mg/kg (40% inhibition, p 0.05).

ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS

The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formula: [Inser